In a strategic move to bolster Egypt’s national pharmaceutical industry, Prof. Dr. Khaled Abdel Ghaffar, Deputy Prime Minister for Human Development and Minister of Health and Population, alongside Prof. Dr. Ali El-Ghamrawy, Head of the Egyptian Drug Authority, Chairman, visited EIPICO Pharmaceuticals’ facilities in the city of Tenth of Ramadan.
These factories, pivotal to the ACDIMA Group, represent the forefront of Egypt’s pharmaceutical advancement.
Welcomed by Dr. Olfat Ghourab, CEO of ACDIMA, and Dr. Ahmed Kilani, Chairman and Managing Director of EIPICO Pharmaceuticals, the visit underscored the Egyptian state’s commitment to ensuring the continuous availability of essential medical products. The initiative aligns with the state’s vision to foster collaboration with industry giants, boosting investment and fortifying the localization of the pharmaceutical sector.
“With a remarkable production rate of 8 billion pounds this year, EIPICO stands as a cornerstone of Egypt’s drug manufacturing industry,” lauded Dr. Khaled Abdel Ghaffar. This remark highlights the strategic role EIPICO plays in the provision of high-quality medical products that meet international standards, thereby enhancing healthcare services for Egyptian citizens.
Dr. El-Ghamrawy further emphasized EIPICO’s vital contributions to meeting Egypt’s medical needs and advancing scientific research, which are crucial for addressing the nation’s healthcare challenges.
The visit also spotlighted the imminent completion of the EIPICO 3 factory, set to be a trailblazer in the Middle East. This facility is poised to produce medicines and biosimilars from the ground up, marking a significant milestone in Egypt’s quest to expand its pharmaceutical footprint both locally and internationally.
This initiative reflects the Egyptian government’s recognition of the pharmaceutical sector’s strategic importance and its unwavering dedication to pioneering pharmaceutical innovation and global competitiveness.